STX-721, a Covalent EGFR/HER2 Exon 20 Inhibitor, Utilizes Exon 20-Mutant Dynamic Protein States and Achieves Unique...

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Epidermal growth factor receptor (EGFR) mutations drive non-small cell lung cancer (NSCLC).
• While some EGFR mutations sensitize tumors to targeted drugs, EGFR exon 20 insertions (ex20ins) confer resistance.
• Existing EGFR inhibitors show limited selectivity, impacting efficacy and causing side effects due to wild-type EGFR inhibition.

Purpose of the Study:

• To understand the structural basis of EGFR ex20ins mutants.
• To design novel inhibitors with enhanced selectivity for EGFR ex20ins mutants over wild-type EGFR.
• To develop STX-721, a potent and selective inhibitor for EGFR ex20ins NSCLC.

Main Methods:

• High-resolution crystal structure determination of EGFR ex20ins mutants.
• Design and synthesis of STX-721, an irreversible EGFR/ERBB2 inhibitor.
• Preclinical evaluation of STX-721 in biochemical, biophysical, cellular, and in vivo assays.

Main Results:

• Structural analysis revealed targetable mutant-biased dynamic protein states in ex20ins mutants.
• STX-721 demonstrated superior selectivity for ex20ins mutants compared to benchmark inhibitors.
• STX-721 achieved selective tumor regression in preclinical models harboring EGFR ex20ins mutations.

Conclusions:

• STX-721 exhibits high mutant EGFR selectivity in preclinical cancer models.
• This selectivity suggests potential for improved clinical efficacy and a better safety profile than existing treatments.
• STX-721 represents a promising therapeutic strategy for NSCLC patients with EGFR ex20ins mutations.